Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation

Rie Yamazaki, Y. Tanaka, H. Nakasone, M. Sato, K. Terasako-Saito, K. Sakamoto, Y. Akahoshi, H. Nakano, T. Ugai, R. Yamasaki, H. Wada, Y. Ishihara, K. Kawamura, M. Ashizawa, S. I. Kimura, M. Kikuchi, S. Kako, J. Kanda, A. Tanihara, J. NishidaY. Kanda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.

Original languageEnglish
Pages (from-to)904-913
Number of pages10
JournalTransplant Infectious Disease
Volume16
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Cytomegalovirus
Immunoglobulin G
Tissue Donors
Hematopoietic Stem Cell Transplantation
Immunoglobulin Allotypes
Antibodies
Humoral Immunity
Immunoglobulin M

Keywords

  • Cytomegalovirus
  • Hematopoietic stem cell transplantation
  • Humoral immunity
  • Immunoglobulin allotypes

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases
  • Medicine(all)

Cite this

Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation. / Yamazaki, Rie; Tanaka, Y.; Nakasone, H.; Sato, M.; Terasako-Saito, K.; Sakamoto, K.; Akahoshi, Y.; Nakano, H.; Ugai, T.; Yamasaki, R.; Wada, H.; Ishihara, Y.; Kawamura, K.; Ashizawa, M.; Kimura, S. I.; Kikuchi, M.; Kako, S.; Kanda, J.; Tanihara, A.; Nishida, J.; Kanda, Y.

In: Transplant Infectious Disease, Vol. 16, No. 6, 01.01.2014, p. 904-913.

Research output: Contribution to journalArticle

Yamazaki, R, Tanaka, Y, Nakasone, H, Sato, M, Terasako-Saito, K, Sakamoto, K, Akahoshi, Y, Nakano, H, Ugai, T, Yamasaki, R, Wada, H, Ishihara, Y, Kawamura, K, Ashizawa, M, Kimura, SI, Kikuchi, M, Kako, S, Kanda, J, Tanihara, A, Nishida, J & Kanda, Y 2014, 'Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation', Transplant Infectious Disease, vol. 16, no. 6, pp. 904-913. https://doi.org/10.1111/tid.12304
Yamazaki, Rie ; Tanaka, Y. ; Nakasone, H. ; Sato, M. ; Terasako-Saito, K. ; Sakamoto, K. ; Akahoshi, Y. ; Nakano, H. ; Ugai, T. ; Yamasaki, R. ; Wada, H. ; Ishihara, Y. ; Kawamura, K. ; Ashizawa, M. ; Kimura, S. I. ; Kikuchi, M. ; Kako, S. ; Kanda, J. ; Tanihara, A. ; Nishida, J. ; Kanda, Y. / Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation. In: Transplant Infectious Disease. 2014 ; Vol. 16, No. 6. pp. 904-913.
@article{cb9a79b7eb0f436d93a22d57a2de2063,
title = "Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation",
abstract = "Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.",
keywords = "Cytomegalovirus, Hematopoietic stem cell transplantation, Humoral immunity, Immunoglobulin allotypes",
author = "Rie Yamazaki and Y. Tanaka and H. Nakasone and M. Sato and K. Terasako-Saito and K. Sakamoto and Y. Akahoshi and H. Nakano and T. Ugai and R. Yamasaki and H. Wada and Y. Ishihara and K. Kawamura and M. Ashizawa and Kimura, {S. I.} and M. Kikuchi and S. Kako and J. Kanda and A. Tanihara and J. Nishida and Y. Kanda",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/tid.12304",
language = "English",
volume = "16",
pages = "904--913",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation

AU - Yamazaki, Rie

AU - Tanaka, Y.

AU - Nakasone, H.

AU - Sato, M.

AU - Terasako-Saito, K.

AU - Sakamoto, K.

AU - Akahoshi, Y.

AU - Nakano, H.

AU - Ugai, T.

AU - Yamasaki, R.

AU - Wada, H.

AU - Ishihara, Y.

AU - Kawamura, K.

AU - Ashizawa, M.

AU - Kimura, S. I.

AU - Kikuchi, M.

AU - Kako, S.

AU - Kanda, J.

AU - Tanihara, A.

AU - Nishida, J.

AU - Kanda, Y.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.

AB - Background: Cytomegalovirus (CMV) reactivation still remains a major problem following allogeneic hematopoietic stem cell transplantation (HSCT). Patients and methods: In this study, we analyzed an immunoglobulin allotype, IgG1m(f), in CMV-seropositive HSCT recipients and their donors to distinguish donor-derived antibody from recipient-derived antibody. Eight donor-recipient pairs were informative regarding the appearance of donor-derived immunoglobulin-G (IgG), as the recipients were homozygous null for the IgG1m(f) allotype and the donors were IgG1m(f) positive. In these patients, total IgG, IgM, and allotype-specific IgG against CMV were measured by enzyme-linked immunosorbent assay. All subjects were monitored for at least 9 months after HSCT with (n = 5) or without (n = 3) CMV reactivation. Results: Donor-derived CMV IgG tended to be elevated earlier in patients with CMV-seropositive donors than in those with CMV-seronegative donors. In 1 patient with a CMV-negative donor, donor-derived CMV IgG was not detected until late CMV reactivation. In 3 patients without CMV reactivation, donor-derived CMV IgG was also elevated within 1-6 months after HSCT. Conclusion: In conclusion, the CMV serostatus of the donor may be related to the timing of the appearance of donor-derived CMV IgG and the reconstitution of humoral immunity against CMV, regardless of the CMV antigenemia level after HSCT.

KW - Cytomegalovirus

KW - Hematopoietic stem cell transplantation

KW - Humoral immunity

KW - Immunoglobulin allotypes

UR - http://www.scopus.com/inward/record.url?scp=84920124373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920124373&partnerID=8YFLogxK

U2 - 10.1111/tid.12304

DO - 10.1111/tid.12304

M3 - Article

C2 - 25367140

AN - SCOPUS:84920124373

VL - 16

SP - 904

EP - 913

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 6

ER -